TherapeuticsMD Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
TXMD$1.69-2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In thousands, except per share amounts)
| Years ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenue, net: | ||
| License and service revenue | $1,302 | $69,963 |
| Total revenue, net | 1,302 | 69,963 |
| Cost of revenue | — | 1,397 |
| Gross profit | 1,302 | 68,566 |
| Operating expenses: | ||
| Selling, general and administrative | 8,903 | 56,710 |
| Depreciation & amortization | 922 | 1,193 |
| Restructuring | — | 9,472 |
| Total operating expenses | 9,825 | 67,375 |
| Income (loss) from operations | (8,523) | 1,191 |
| Other income (expense): | ||
| Miscellaneous income (expense) | 781 | (117) |
| Total other income (loss), net | 781 | (117) |
| Income (loss) from continuing operations before income taxes | (7,742) | 1,074 |
| Benefit (provision) for income taxes | 43 | — |
| Net income (loss) from continuing operations | (7,699) | 1,074 |
| Income (loss) from discontinued operations, net of income taxes | (2,579) | 110,923 |
| Net income (loss) | $(10,278) | $111,997 |
| Income (loss) per common share, basic: | ||
| Continuing operations | (0.74) | 0. 12 |
| Discontinued operations, net | (0.25) | 12.29 |
| Net income (loss) per common share, basic | $(0.98) | $12.41 |
| Income (loss) per common share, diluted: | ||
| Continuing operations | (0.74) | 0.11 |
| Discontinued operations, net | (0.25) | 11.84 |
| Net income (loss) per common share, diluted | $(0.98) | $11.96 |
| Weighted average common shares, basic | 10,441 | 9,028 |
| Weighted average common shares, diluted | 10,441 | 9,366 |
| Net income (loss) | $(10,278) | $111,997 |
| Other comprehensive income | — | — |
| Comprehensive income (loss): | $(10,278) | $111,997 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.